Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-
nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …

Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Abstract Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in
FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose
incidence is increasing. Largely neglected for decades as a rare malignancy and frequently …